Amol Akhade: Cabozantinib plus Atezolizumab vs second-line NHT in prostate cancer

Amol Akhade shared a post on LinkedIn:

”Cabozantinib plus Atezolizumab versus second-line Non-hormonal Therapy (NHT) in prostate cancer sparked discussions at ESMO24.

The trial highlighted an inappropriate control arm, particularly for patients receiving Enzalutamide after Abiraterone.

Notably, the study showed marginal progression-free survival benefits in bone-only metastases subgroup but lacked such impact in liver metastases.

Despite the trial’s positive label, the absence of overall survival benefits (curves are stuck to each other) and the decision by primary company to go against regulatory approval process for the same indication indicate a shift towards a more realistic approach.

With over 700 million USD invested in studying prostate cancer drugs with more than 7000 patients, it’s crucial to reassess the value of immunotherapy in this context.

This study underscores the limited efficacy of immunotherapy in prostate cancer, prompting a reevaluation of treatment strategies. It may be time to redirect resources and efforts towards more promising avenues in prostate cancer research.”

Source: Amol Akhade/LinkedIn

Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.